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plasma chemokines are biomarkers 
of disease severity, higher bacterial 
burden and delayed sputum 
culture conversion in pulmonary 
tuberculosis
nathella p. Kumar1, Kadar Moideen1, Arul nancy1,2, Vijay Viswanathan2, 
Basavaradhya S. Shruthi2, Shanmugam Sivakumar3, Mohan natarajan3,  
Hardy Kornfeld  4 & Subash Babu1,5*
plasma cytokines are biomarkers of disease extent and mycobacterial burden in pulmonary tuberculosis 
(ptB). Whether chemokines can perform the same role in ptB is not known. We examined the plasma 
levels of chemokines in individuals with ptB, latent tB (LtB) or healthy controls (Hc) and their 
association with disease severity and mycobacterial burdens in ptB. We also examined the chemokines 
in ptB individuals at the end of anti-tuberculous chemotherapy (Att). ptB individuals exhibited 
significantly higher levels of CCL1, CCL3, CXCL1, CXCL2, CXCL9 and CXCL10 in comparison to LTB and/
or HC individuals. PTB individuals with bilateral or cavitary disease displayed significantly elevated 
levels of CCL1, CCL3, CXCL1, CXCL10 and CXCL11 compared to those with unilateral or non-cavitary 
disease and also exhibited a significant positive relationship with bacterial burdens. In addition, PTB 
individuals with slower culture conversion displayed significantly elevated levels of CCL1, CCL3, CXCL1 
and CXCL9 at the time of PTB diagnosis and prior to ATT. Finally, the chemokines were significantly 
reduced following successful Att. our data demonstrate that ptB is associated with elevated levels 
of chemokines, which are partially reversed followed chemotherapy. our data demonstrate that 
chemokines are markers of disease severity, predicting increased bacterial burden and delayed culture 
conversion in ptB.
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis (Mtb), is the world’s leading cause of infectious 
disease mortality1. There are over 2 billion infected with Mtb worldwide and approximately 5–10% of infected 
individuals are thought to progress to active TB in their lifetime1. Infection with Mtb involves a spectrum of 
disease progression steps with latent infection and active disease being interspersed with incipient TB and sub-
clinical TB2. Moreover, the clinical manifestations of TB disease are not uniform but might vary depending on the 
bacterial burden and disease severity3. Severe disease is thought to involve both the lungs (bilateral disease) and 
more of cavitary lesions, the latter of which is postulated to be associated with increased transmission1. Bacterial 
burden is reflected by the number of bacteria in the sputum as estimated by smear or culture. However, the immu-
nological underpinnings of these disease manifestations remain incompletely understood.
Chemokines are felt to play a major role latent TB infection (LTB) as they appear to be critical in the formation 
and maintenance of quiescent granulomas4 and in the recruitment of cells from the periphery for positioning 
within the granuloma5. Establishment of the TB granuloma is controlled by the synchronized expression of var-
ious chemokines. However, chemokines, like cytokines, are a double-edged sword in infectious disease and can 
play a detrimental role in pathogenesis6. Thus, excessive levels of certain chemokines can drive the enhanced 
infiltration of neutrophils and monocytes to the site of infection, which might augment immune mediated 
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pathology6,7. An optimal balance between protective and pathological immune responses at the site of infection 
in TB might be reflected by the levels of chemokines in the circulation8. Chemokines, categorized within four 
families (C, CC, CXC, CX3C), are essential in regulating inflammation, leukocyte recruitment and antimicrobial 
immunity9,10. The CC chemokines - CCL3, CCL4, CCL5 and CCL8 as well as the CXC chemokines - CXCL9, 
CXCL10 and CXCL11 are upregulated in Mtb-infected mice6,11. These chemokines play an important role in the 
recruitment of T cells and other cells to the lung during early infection11. Finally, defects in the production of 
certain chemokines have been associated with increased susceptibility to Mtb in animal models5,6.
Our previous work has also demonstrated that plasma cytokines are biomarkers of disease severity, mycobac-
terial burden and slower culture conversion in PTB12. To decipher the role of chemokines in TB infection and 
disease, we measured the levels of chemokines in PTB, LTB and HC individuals. Our goal was to correlate the 
levels of these chemokines with the extent and severity of disease, sputum bacterial burden, and time to culture 
conversion and to evaluate the longitudinal changes in chemokine levels before and after anti-TB treatment. Our 
data demonstrate that chemokines were indeed markers of disease severity, bacterial burden and time to culture 
conversion in PTB.
Results
Study demographics. All participants did not exhibit signs or symptoms of other lung disease. The individ-
uals in the two groups were not significantly different in terms of age and gender and the baseline characteristics 
of the study participants are shown in Table 1. ATT was given to PTB individuals using the directly observed 
treatment, short course (DOTS) strategy. All PTB individuals were sputum culture negative at six months of 
treatment.
plasma levels of chemokines are elevated in ptB. To examine the systemic levels of chemokines 
in TB infection and disease, we measured the plasma levels of CCL1, CCL2, CCL3, CXCL1, CXCL2, CXCL9, 
CXCL10 and CXCL11 in PTB, LTB and HC individuals (Fig. 1). As shown in Fig. 1A, the systemic levels of CCL1 
(Geometric Mean of 6.97 pg/ml in PTB versus 4.06 pg/ml in LTB and 3.69 pg/ml in HC), CXCL1 (GM of 226.1 pg/
ml in PTB versus 150.3 pg/ml in LTB and 115.4 pg/ml in HC), CXCL2 (GM of 1309 pg/ml in PTB versus 921.3 pg/
ml in LTB and 597.4 pg/ml in HC), CXCL9 (GM of 545.1 pg/ml in PTB versus 296.4 pg/ml in LTB and 186.1 pg/
ml in HC) and CXCL10 (GM of 160.2 pg/ml in PTB versus 101.1 pg/ml in LTB and 63.8 pg/ml in HC) were sig-
nificantly higher in PTB compared to both LTB and HC individuals, while the levels of CCL3 (GM of 56.7 pg/
ml in PTB versus 49.3 pg/ml in LTB and 37.45 pg/ml in HC) was significantly higher in PTB compared to HC 
individuals. Next, PCA using the above set of chemokines clearly demonstrated the ability of these cytokines to 
discriminate PTB from LTB or HC individuals. Finally, ROC analysis of CCL1, CXCL1, CXCL2, CXCL9, CXCL10 
and CXCL11 was performed in PTB vs LTB individuals (Fig. 1C). As shown in Fig. 1C, CCL1, CXCL9, CXCL10 
and CXCL11 exhibited significant discriminatory power with moderate area under the curve (AUC) values and 
sensitivity and specificity in discriminating PTB from LTBI individuals. Thus, PTB individuals display signifi-
cantly elevated systemic levels of chemokines.
plasma chemokines are markers of disease severity in ptB. To examine the association between 
the systemic levels of chemokines and disease severity and extent in PTB, we measured the plasma levels of 
CCL1, CCL2, CCL3, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 in PTB individuals with unilateral ver-
sus bilateral disease and with cavitary versus non-cavitary disease (Fig. 2). As shown in Fig. 2A, the systemic 
levels of CCL1 (GM of 7.64 pg/ml in bilateral vs. 5.53 pg/ml in unilateral disease), CCL3 (GM of 63.98 pg/ml 
in bilateral vs. 46.08 pg/ml in unilateral disease), CXCL1 (GM of 251.5 pg/ml vs. 186.6 pg/ml), CXCL2 (GM of 
1488 pg/ml vs. 1047 pg/ml), CXCL10 (GM of 187.8 pg/ml vs. 121.2 pg/ml) and CXCL11 (GM of 334.3 pg/ml vs. 
148.3 pg/ml) were significantly increased in PTB individuals with bilateral disease compared to unilateral disease. 
Similarly, as shown in Fig. 2B, the systemic levels of CCL1 (GM of 10.51 pg/ml in cavitary disease vs. 5.65 pg/ml in 
non-cavitary disease), CCL3 (GM of 48.55 pg/ml vs. 50.22 pg/ml), CXCL1 (GM of 284.3 pg/ml vs. 202.2 pg/ml), 
CXCL9 (GM of 657.3 pg/ml vs. 381.8 pg/ml), CXCL10 (GM of 216.5 pg/ml vs. 141,1 pg/ml) and CXCL11 (GM of 
375.4 pg/ml vs. 209.3 pg/ml) were significantly increased in PTB individuals with cavitary disease compared to 
those without cavitary disease. Thus, disease severity and extent in PTB is associated with increased plasma levels 
of chemokines.
Study Demographics PTB LTB HC
Number of subjects recruited 88 44 44
Gender (Male/Female) 61/27 30/14 28/16
Median Age (Range) 48 (25–70) 40 (25–67) 32 (23–55)
Smear Grade: 0/1+/2+/3+ 0/32/27/29 — —
Lung lesions (Bilateral/Unilateral) 56/32 — —
Cavity (Cavity/No Cavity) 26/62
Quantiferon TB Gold in Tube — Positive Negative
Tuberculin Skin Test — Positive Negative
Table 1. Demographics of the study groups.
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plasma chemokines are markers of bacterial burdens and delayed sputum culture conversion in ptB. 
To examine the association between the systemic levels of chemokines and bacterial burden in PTB, we performed 
a correlation of the plasma levels of CCL1, CCL2, CCL3, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11in PTB 
individuals with smear grade classified as 1+, 2+ and 3+ (Fig. 3). As shown in Fig. 3A, the systemic levels of 
CCL1, CCL2, CXCL1, CXCL9, CXCL10 and CXCL11 displayed a significant positive correlation with smear 
grades in PTB individuals, indicating a positive relationship of chemokines with bacterial burdens. To determine 
whether chemokines could serve as predictive biomarkers for delayed culture conversion in PTB, we measured 
the plasma levels of CCL1, CCL2, CCL3, CXCL1, CXCL2, CXCL9, CXCL10 and CXCL11 in PTB individuals at 
baseline (prior to commencement of treatment) and correlated to those who had positive cultures at 2 months 
(slow responders, SR) and those who had negative cultures at 2 months (fast responders, FR). As shown in Fig. 3B, 
the systemic levels of CCL1 (GM of 8.60 pg/ml in SR vs. 5.04 pg/ml in FR), CCL3 (GM of 75.34 pg/ml vs. 45.34 pg/
ml), CXCL1 (GM of 215.2 pg/ml vs. 235.2 pg/ml) and CXCL9 (GM of 690 pg/ml vs. 451.8 pg/ml) were signifi-
cantly higher in slow responders compared to fast responders. Finally, as shown in Fig. 3C, we also performed 
Figure 1. Elevated plasma levels of chemokines in PTB individuals (A) The plasma levels of chemokines were 
measured in PTB (n = 88), LTB (n = 44) and HC (n = 44) individuals. The data are represented as scatter plots 
with each circle representing a single individual. P values were calculated using the Kruskal-Wallis test with 
Dunn’s post hoc comparison. (B) PCA (Principle component analysis) plot computing normalized ELISA 
data from baseline plasma levels of cytokines in combination of two different experimental groups first PTB 
(Colored in blue) vs LTB (Colored in red) and second PTB (Colored in blue) vs HC (Colored in red). (C) 
ROC analysis to estimate the sensitivity, specificity and AUC was performed using chemokines to estimate the 
capacity of these factors to distinguish individuals with PTB vs. LTB.
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ROC analysis to determine the strength of plasma chemokines to distinguish SR from FR in the PTB individu-
als. While CCL1, CCL3 and CXCL9 all exhibited a significant area under the curve, only CCL3 exhibited high 
sensitivity and specificity in discriminating SR from FR. Combination of different chemokines did not provide 
additional predictive power over individual values. Thus, plasma chemokines are also markers of delayed culture 
conversion in PTB.
Plasma chemokine levels are significantly diminished following ATT. To examine whether the ele-
vated levels of chemokines are directly linked with TB disease, we measured the levels of these chemokines in 
PTB individuals before and after a regimen of ATT (pre-T versus post-T). As shown in Fig. 4, at the end of ATT, 
the plasma levels of CCL1 (GM of 6.79 pg/ml pre-T vs. 0.88 pg/ml post-T), CCL2 (GM of 49.02 pg/ml vs. 19.37 pg/
ml), CXCL2 (GM of 1309 pg/ml vs. 361.3 pg/ml), CXCL9 (GM of 545.1 pg/ml vs. 237.4 pg/ml), CXCL10 (GM of 
160.2 pg/ml vs. 41.23 pg/ml) and CXCL11 (GM of 248.7 pg/ml vs. 28.71 pg/ml) were all significantly decreased 
compared to pre-treatment levels. Thus, chemokine levels are significantly decreased in PTB following successful 
chemotherapy.
Discussion
Chemokines are major mediators of resistance in TB and these findings are mostly derived from animal models 
of infection5. However, these data also indicate that chemokines can serve as a double - edged sword with both 
the levels and timing of chemokine production serving as the balance of protection versus pathology6. Following 
infection, the interplay of pro-inflammatory and anti-inflammatory signals is important in the establishment and 
maintenance of the the tuberculosis granuloma2,13. A push towards a robust pro-inflammatory chemokine milieu 
can precipitate bacterial dissemination, with resultant changes in the granuloma architecture and damage of lung 
parenchyma2,14. These processes determine the activation of Tb disease and help promote transmission of infec-
tion. In our study, we demonstrate that heightened levels of chemokines are a major feature of PTB disease and 
serve as biomarkers of disease severity/extent and mycobacterial burden and can be modulated by chemotherapy.
Our data show that the CC chemokines – CCL1 and CCL3 as well as the CXC chemokines – CXCL1, CXCL2, 
CXCL9 and CXL10 are present at significantly elevated concentrations in the plasma of PTB individuals. It is 
possible that concentrations of chemokines at the site of infection has a more direct effect on host resistance to 
infection and disease. Our data also demonstrates the moderate sensitivity and specificity (by ROC analysis) 
offered by plasma chemokine measurements in distinguishing PTB from LTB individuals. In addition, our data 
reveals the lack of differences in the chemokine levels between latent TB infection and healthy controls. Future 
studies need to elucidate the role of these chemokine alterations in immune cell recruitment.
Biomarkers of TB disease severity and extent as well as blood markers of bacterial burdens are important tools 
in the progress towards elimination of TB15. Our data reveal that chemokines can serve as important biomarkers 
Figure 2. Plasma chemokines are associated with extent of disease, or disease severity in PTB individuals (A) 
The plasma levels of chemokines were measured in in PTB individuals with bilateral versus unilateral disease, 
reflecting the extent of disease. (B) The plasma levels of chemokines were measured in PTB individuals with 
cavitary versus non-cavitary disease, reflecting the disease severity. The data are represented as scatter plots with 
each circle representing a single individual. P values were calculated using the Mann-Whitney test with Holm’s 
correction for multiple comparisons.
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of disease severity (cavity or no cavity) and extent (unilateral or bilateral), since higher levels of CCL1, CCL3, 
CXCL1, CXCL10 and CXL11 are reflective of the disease severity and extent. In addition, CXCL2 for disease 
extent and CXCL9 for disease severity can also serve as plasma biomarkers. Our study also reveals that the same 
set of chemokines that serve as biomarkers of disease pathology can also serve as biomarkers of bacterial burdens 
Figure 3. Plasma chemokines are associated with bacterial burdens in PTB individuals (A) The relationship 
between the plasma levels of chemokines and smear grades as estimated by sputum smears was examined in 
PTB individual. The data are represented as scatter plots with each circle representing a single individual. P 
values were calculated using the Linear trend post – test. (B) The plasma levels of chemokines at baseline were 
measured in PTB individuals, who were slow responders (Sputum positive during 2nd month of ATT, SR) versus 
fast responders (Sputum negative during 2nd month of ATT, FR). The data are represented as scatter plots with 
each circle representing a single individual. P values were calculated using the Mann-Whitney test with Holm’s 
correction for multiple comparisons. (C) ROC analysis to estimate the sensitivity, specificity and AUC was 
performed using chemokines to estimate the capacity of these factors to distinguish SR from FR.
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and time to culture conversion. Thus, plasma levels of CCL1, CCL2, CXCL1, CXCL9, CXCL10 and CXCL11 are 
indicative of bacterial burdens with PTB individuals having the highest burdens exhibiting the highest levels of 
these chemokines. Moreover, PTB individuals who are culture positive at 2 months of ATT have significantly 
higher levels of CCL1, CCL3, CXCL1 and CXCL9 before commencement of ATT, indicating that baseline levels 
of these chemokines are markers of time to culture conversion and can be promising immunological predictors 
of culture conversion. Hence, measurement of plasma chemokines, especially CCL3, which could be done a base-
line, might stratify patients who require intensified treatment e.g. high-dose rifampicin. This would particularly 
be the case if the chemokines outperformed baseline sputum smear grade for predicting outcomes, which needs 
to be tested in future studies. It should be noted that all PTB individuals were culture negative at the end of ATT 
and thus we could not ascertain the utility of these chemokines in prediction of treatment failure. Previous studies 
have shown that CXCL9 and CXCL10 are good biomarkers to distinguish PTB from LTB and that these markers 
significantly decrease following ATT16,17. Our study adds to this panel of host chemokines that can be used to 
monitor treatment responses since plasma levels of CCL1, CCL2, CXCL2, CXCL9, CXCL10 and CXCL11 are all 
significantly lowered following ATT.
Host biomarker studies have largely placed CXCL10 at the center of interest in the immunodiagnosis of 
TB18,19. Studies have shown that plasma levels of CXCL10 in active TB patients are significantly elevated after 
stimulation20, as well as exhibit greater sensitivity when discriminating between active TB and LTB, compared 
to using IFNγ alone17,21. The other promising chemokine studied thus far as a biomarker for TB is CXCL922–24. 
Our study expands on this panel of chemokines and demonstrates that a larger panel of chemokines can serve as 
moderately good biomarkers of disease severity, bacterial burden and treatment monitoring. This includes CCL1, 
CCL3 and CXCL1. Our study has several positives including the large sample size, the use of bacteriologically 
proven (culture positive) PTB individuals with follow up and clearly delineated controls. However, our study only 
examines associations between chemokines and TB disease and cannot attribute any cause-effect relationship or 
delineate the mechanistic underpinnings of the role of chemokines in TB disease. Nevertheless, our data make 
a compelling argument for the continued evaluation of chemokines as an adjunct tool to evaluate TB disease in 
endemic populations and validate its utility for a point-of-care assay as a rule out or triage test for TB.
Methods
ethics statement. This study was approved by the Ethics Committees of the Prof. M. Viswanathan Diabetes 
Research Center (ECR/51/INST/TN/2013/MVDRC/01) and NIRT (NIRT-INo:2014004). Informed written con-
sent was obtained from all participants. All the methods were performed in accordance with institutional ethical 
committee guidelines. The study participants were recruited from the Effect of Diabetes in Tuberculosis Severity 
protocol conducted under the RePORT India consortium25. These participants were different from the partici-
pants in our previous study on cytokines in TB disease12, which was conducted at NIRT alone and this study was 
from a separate protocol.
Figure 4. Diminished plasma levels of chemokines at the end of standard anti-tuberculosis therapy in PTB 
individuals. (A) The plasma levels of chemokines were measured in PTB at baseline (pre-T) and at 6 months 
of ATT (post-T). The data are presented as line graphs with each line representing a single individual. P values 
were calculated using the Wilcoxon signed rank test.
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Study population. Plasma samples were collected by centrifuging the whole blood specimen at 2600 rpm for 
10 mins from 88 individuals with active pulmonary TB (PTB), 44 individuals with latent TB (LTB) and 44 indi-
viduals with no TB infection or disease (HC), recruited in Chennai, India. Individuals with pulmonary TB were 
diagnosed by positive solid cultures in Lowenstein–Jensen medium and were classified as 1+ (10–100 colonies), 
2+ (>100–200 colonies) and 3+ (>200 colonies). Chest radiographs on enrollment were graded by two blinded 
readers using a validated severity score based on the percent area of lung involved with TB disease and the pres-
ence or absence of cavities. Smear grades were used to determine bacterial burdens and classified as 1+ (10–99 
AFB in 100 fields), 2+ (1–10 AFB in each field) and 3+ (more than 10 AFB in each field). Culture conversion 
(from positive to negative) at 2 months was defined as the cut-off for fast responders (FR, who culture converted) 
versus slow responders (SR, who were still culture positive). At the time of enrollment, all active TB cases had no 
record of prior TB disease or anti-TB treatment (ATT). Tuberculin skin test was performed using two tuberculin 
units of Tuberculin Purified Protein Derivative RT 23 Serum Statens Institute. A positive skin test was defined 
as an induration of at least 12-mm diameter based on the previously determined cutoff norms for South India 
and Quantiferon TB-Gold in Tube ELISA positivity, absence of chest radiograph abnormalities or pulmonary 
symptoms and negative sputum smears. HC individuals were asymptomatic with normal chest X-rays, negative 
TST (indurations <5 mm in diameter) and Quantiferon results. Study enrolled participants were BCG vaccinated, 
HIV negative, non-diabetic and had normal body mass index (BMI, between 18.5 and 24.9 kg/m2).
eLiSA. Circulating levels of chemokines were measured using Bio-Plex multiplex assay system (Bio-Rad, 
Hercules, CA). Luminex Human Chemokines Magnetic Assay kit (R & D systems) was used to measure the 
chemokine levels. The lowest detection limits were as follows: CCL1, 1.57 pg/mL; CCL2, 31.8 pg/mL; CCL3, 
90.9 pg/mL; CXCL1, 49.2 pg/mL; CXCL2, 49.2 pg/mL; CXCL9, 600.6 pg/mL CXCL10, 2.88 pg/mL and CXCL11, 
21.6 pg/mL.
Statistical analysis. Geometric means (GM) were used for measurements of central tendency. Statistically 
significant differences between the three groups were analyzed using the Kruskal-Wallis test with Dunn’s multiple 
comparisons. Principal component analysis (PCA) was done using statistical software JMP 13.0 (SAS, Cary, NC, 
USA). Receiver operator characteristics (ROC) curves were designed to test the power of each candidate chemok-
ine to distinguish LTB from PTB and SR from FR in PTB. Mann-Whitney test was used to compare chemokine 
concentrations in PTB individuals with unilateral or bilateral lung lesions or cavitary or non-cavitary disease and 
slow responders or fast responders with Holm’s correction for multiple comparisons. Linear trend post-test was 
used to compare chemokine concentrations with smear grades (reflecting bacterial burdens). Wilcoxon signed 
rank test was used to compare chemokine concentrations before and after ATT. Analyses were performed using 
Graph-Pad PRISM Version 7.0.
Data availability
All data are available in the manuscript and figures.
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